Evidence map›Paper›PMID 41002551›Full record

ArticleCurrent oncology (Toronto, Ont.)2025

Liver Transplantation for Unresectable Colorectal Liver Metastases: A Scoping Review on Redefining Boundaries in Transplant Oncology.

Berkay Demirors, Vrishketan Sethi, Abiha Abdullah, Charbel Elias, Francis Spitz, Jason Mial-Anthony, Godwin Packiaraj, Sabin Subedi, Shwe Han, Timothy Fokken and 1 more

Abstract readScoping Review
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Berkay DemirorsDepartment of Surgery, Division of Abdominal Organ Transplant Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.
Vrishketan SethiDepartment of Surgery, Division of Abdominal Organ Transplant Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.
Abiha AbdullahDepartment of Surgery, Division of Abdominal Organ Transplant Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.
Charbel EliasDepartment of Surgery, Division of Abdominal Organ Transplant Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.
Francis SpitzDepartment of Surgery, Division of Abdominal Organ Transplant Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.
Jason Mial-AnthonyDepartment of Surgery, Division of Abdominal Organ Transplant Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.ORCID 0009-0007-4170-8469
Godwin PackiarajDepartment of Surgery, Division of Abdominal Organ Transplant Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.
Sabin SubediDepartment of Surgery, Division of Abdominal Organ Transplant Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.ORCID 0009-0001-5939-5268
Shwe HanDepartment of Surgery, Division of Abdominal Organ Transplant Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.ORCID 0000-0002-8995-4083
Timothy FokkenDepartment of Surgery, Division of Abdominal Organ Transplant Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.
Michele MolinariDepartment of Surgery, Division of Abdominal Organ Transplant Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.ORCID 0000-0002-9763-6253

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Historically, colorectal liver metastases (CRLMs) have been considered a contraindication for liver transplantation (LT), primarily due to limited organ availability and concerns about oncologic efficacy. However, emerging evidence indicates that highly selected patients with unresectable CRLM can achieve long-term survival following LT-often with outcomes superior to those obtained through conventional systemic therapies. To evaluate the evolving role of LT in this setting, we conducted a scoping review of the literature. A comprehensive search was performed across PubMed, Embase, Web of Science, Scopus, and ClinicalTrials.gov, as well as ProQuest Dissertations & Theses and Google Scholar to capture gray literature. The search included English-language articles published between January 2015 and April 2025. Eligible studies included those reporting on the application of LT for patients with unresectable CRLM. This scoping review synthesizes current evidence on patient selection criteria, overall and disease-free survival, recurrence patterns, and emerging biomarkers that may guide transplant eligibility. In addition, we explore innovations in organ utilization-including living donor LT and machine perfusion technologies-that aim to expand access while addressing ethical concerns related to organ allocation. As LT for CRLM transitions from investigational use to clinical implementation, this review outlines the key challenges and future opportunities that will shape its role in the landscape of transplant oncology.

Indexed as

Colorectal NeoplasmsLiver NeoplasmsLiver TransplantationHumanscolorectal cancercolorectal liver metastasesdisease free survivalliver transplantationoverall survivalpatient selection

Identifiers

PMID41002551
PMCPMC12468046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.